Skip to main content
. 2022 Apr 26;13:849189. doi: 10.3389/fphar.2022.849189

FIGURE 2.

FIGURE 2

| One-way sensitivity analysis results of the FOLFOX-HAIC strategy versus TACE strategy in all patients with large unresectable hepatocellular carcinoma. The tornado diagram shows the impact of varying model parameters on the incremental cost-effectiveness ratio of the FOLFOX-HAIC strategy compared to the TACE strategy. The dotted line intersecting the blue and yellow bar represents the ICER of $30,552/QALY from the base case results. OS, overall survival; PFS, progression-free survival; HR, hazard ratio; TACE, transarterial chemoembolization; FOLFOX-HAIC, hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; PFD, progression-free disease; PD, progressed disease; BSC, best supportive care.